Collectively, these results point to the expression of BIM as a potential predictive biomarker, and support the applicability of DBP in NSCLC patient-derived cells to rapidly identify BIM-mediated apoptotic cell death. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.